ReviewThe Use of Vaccines in Adult Patients With Renal Disease
Section snippets
Hepatitis B
Hepatitis B virus (HBV) has been a public health issue in dialysis units since the advent of hemodialysis in the 1960s, and it has remained the main infectious target of vaccination in the dialysis population. HBV is transmitted by percutaneous or mucosal exposure to infectious blood or body fluids. It is relatively stable in the environment, remaining viable on environmental surfaces at room temperature for at least 7 days. Therefore, blood-contaminated surfaces such as equipment, supplies,
Streptococcus Pneumoniae
Pneumonia remains a major cause of morbidity and mortality in patients with renal disease. According to the most recent US Renal Data System (USRDS) report, rates of pneumonia during the first year of hemodialysis have increased gradually from 24.8 admissions/100 patient-years at risk in 1991 to 30.6 admissions/100 patient-years at risk in 2001.1 Slinin et al33 reported an overall pneumonia hospitalization rate of 84.4 admissions/1,000 patient-years in 14,859 prevalent hemodialysis patients. S
Influenza
Influenza epidemics have been responsible for an average of 36,000 deaths/y in the United States between 1990 and 1999.48 Patients on dialysis therapy are at greater risk for influenza-related mortality.49 Influenza vaccination is associated with decreases in influenza-related respiratory illness, physician visits in all age groups, hospitalization and death in persons at high risk, otitis media in children, and work absenteeism in adults.48 Although influenza vaccination rates in the general
Tetanus and Diphtheria
Since the introduction of vaccination with tetanus toxoid in the 1940s, tetanus has been a rare disease in the United States, with an overall incidence of 0.02 cases/100,000 population during the late 1990s.46 The majority of cases reported occurred in persons who had not completed a 3-dose primary tetanus toxoid vaccination or for whom vaccination histories were uncertain. Adults aged 60 or older are at greatest risk for tetanus and tetanus-related mortality, with an incidence of 0.03
Hepatitis A
In most industrialized countries, there are low levels of endemic hepatitis A virus (HAV) transmission. Because most of the population in these countries are susceptible to HAV infection, outbreaks occur.70 In the United States, this is becoming more apparent with the importation of food that may be tainted.70, 71
HAV causes both acute disease and asymptomatic infection, but does not cause chronic infection. It confers lifelong immunity from future HAV infection.72 Patients with chronic liver
Varicella Vaccine
Approximately 4 million varicella cases with 4,000 to 9,000 hospitalizations and 100 deaths were reported annually in the United States before the approval of varicella vaccine in 1995 (Varivax; Merck). Although less than 5% of these cases occurred in adults older than 20 years, 55% of varicella-related deaths occurred in this age group.81 The incidence of varicella infection in patients with renal disease is not clearly defined. Although varicella is not a significant contributor to morbidity
Staphylococcus Aureus Vaccine
S aureus remains a major cause of morbidity in hemodialysis patients. An annual incidence of bacteremia caused by S aureus of 3% to 4% in hemodialysis patients was reported in the early 1990s.89 Most recent USRDS data showed that adjusted septicemia rates in the first year of dialysis therapy increased from 13.96/100 patients in 1991 to 26.16/100 patients in 2001 (Fig 3), with S aureus as the most common specified organism.3 Danese et al recently showed that septicemia caused by S aureus was
Conclusion
Vaccines remain an underused tool for the prevention of infectious complications in patients with renal disease. Nephrologists frequently serve as primary care physicians for their patients and thus need to be familiar with the data for commonly used adult vaccinations. Although patients with renal disease may have an impaired immunologic response, successful vaccination of this patient population is possible and can decrease the risk for complications from vaccine-preventable diseases. Recent
References (92)
- et al.
Protective effect of hepatitis B vaccine in chronic hemodialysis patients
Am J Kidney Dis
(1999) - et al.
Vaccine induced immunologic memory for hepatitis B surface antigenImplications for policy on booster vaccination
Vaccine
(1996) - et al.
Comparison of the cost and effectiveness of two strategies for maintaining hepatitis B immunity in hemodialysis patients
Vaccine
(2002) - et al.
A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients
Am J Kidney Dis
(2000) - et al.
Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination
Am J Kidney Dis
(1998) - et al.
Randomised placebo-controlled trial of recombinant interleukin in chronic uraemic patients who are non-responders to hepatitis vaccine
Lancet
(1994) - et al.
A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant
Vaccine
(2003) - et al.
Stage of chronic kidney disease predicts seroconversion after hepatitis B immunizationEarlier is better
Am J Kidney Dis
(2003) - et al.
Hepatitis B vaccination and booster in predialysis patientsA 4-year analysis
Vaccine
(1993) - et al.
Immunogenicity of a recombinant DNA hepatitis B vaccine in renal transplant patients
Vaccine
(1993)
Pneumonia in kidney allograft recipients
Transplant Proc
Pulmonary infectious mortality among patients with end-stage renal disease
Chest
Persistence of antibodies to pneumococcal vaccine in patients with chronic renal failure
Kidney Int
Pneumococcal vaccination in patients with chronic renal disease and renal allograft recipients
Kidney Int
Trivalent influenza vaccine in patients on haemodialysisImpaired seroresponse with differences for A-H3N2 and A-H1N1 vaccine components
Vaccine
Antibody responses to influenza vaccination in patients with chronic renal failure
Kidney Int
Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients
Vaccine
Reduction in mortality associated with influenza vaccine during 1989-90 epidemic
Lancet
Influenza vaccine delivery and effectiveness in end-stage renal disease
Kidney Int
Influenza virus infection in adult solid organ transplant recipients
Am J Transplant
Tetanus immunization and its association to hepatitis B vaccination in patients with chronic renal failure
Am J Kidney Dis
A 5-year follow-up on antibody response after diphtheria and tetanus vaccination in hemodialysis patients
Am J Kidney Dis
Herpes zoster infection following solid organ transplantationIncidence, risk factors and outcomes in the current immunosuppressive era
Am J Transplant
USRDS 2004 Annual Data Report
Immunization practices in children with renal diseaseA report of the North American Pediatric Renal Transplant Cooperative Study
Pediatr Nephrol
Recommended adult immunization schedule—US, 10/2004-9/05
MMWR Morb Mortal Wkly Rep
Infections in patients with CRF
Infect Dis Clin North Am
Recommendations for preventing transmission of infections among chronic HD patients
MMWR Morb Mortal Wkly Rep
Duration of hepatitis B surface antigenemia (HBsAg) in hemodialysis patients
Arch Intern Med
HepatitisControl Measures for Hepatitis B in Dialysis Centers
National surveillance of dialysis-associated diseases in the United States, 2001
Semin Dial
Outbreaks of hepatitis B infection among HD patients—California, Nebraska, Texas, 1994
MMWR Morb Mortal Wkly Rep
An outbreak of hospital-acquired hepatitis B virus infection among patients receiving chronic hemodialysis
Infect Control Hosp Epidemiol
Vaccination against hepatitis BResults of the analysis of 2000 population members in Croatia
Eur J Epidemiol
Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy
N Engl J Med
Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patientsA prospective randomized study with cost-effectiveness evaluation
Nephrol Dial Transplant
The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on hepatitis B vaccination in haemodialysis patients
J Viral Hepat
Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona
Nephrol Dial Transplant
CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adultsA double-blind phase I/II study
J Clin Immunol
CpG oligodeoxynucleotides improve the response to hepatitis B immunization in healthy and SIV-infected rhesus macaques
AIDS
Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure
J Assoc Physicians India
A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients
Health Serv Res
Impact of hepatitis B and C virus on kidney transplantation outcome
Hepatology
Immunogenicity of hepatitis B vaccine in renal transplant recipients
Transplantation
Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP)
MMWR Morb Mortal Wkly Rep
Clinical epidemiology of pneumonia in hemodialysis patients
J Am Soc Nephrol
Cited by (91)
Chinese Clinical Practice Guideline for the Management of “CKD-PeriDialysis”-the Periods Prior to and in the Early-Stage of Initial Dialysis
2022, Kidney International ReportsCitation Excerpt :1.2.1 Dialysis isolation and disinfection systems should be implemented. Disposable dialyzers are recommended but if reusable dialyzers are used, the relevant guidelines for infection control should be strictly adhered to.76,116 1.2.2 Clinicians should ensure that hemodialysis related materials have been disinfected, and there is adequate cleaning of the dialysis environment, such as the dialysis room and equipment, to avoid cross infection.
The Interdisciplinary Clinic for Chronic Kidney Disease
2019, Chronic Renal DiseaseCancer in dialysis and transplant patients
2019, Kidney Transplantation - Principles and Practice
The data reported here have been supplied by the US Renal Data System. The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.
Originally published online as doi:10.1053/j.ajkd.2005.08.032 on November 3, 2005.